Mississauga, ON -- (SBWIRE) -- 10/23/2017 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "ATOS Stock Gains On Call to Discuss Results from Phase 1 Trial."
Companies mentioned in this article include Atossa Genetics (NASDAQ:ATOS).
Article Excerpt:
Investors are apparently looking forward to getting some insight on how Atossa Genetics (NASDAQ:ATOS) fared in its early-stage study of its experimental oral drug endoxifen. Endoxifen is the active ingredient in the commonly-used tamoxifen, a drug first approved by the FDA 40 years ago used to treat breast cancer and in breast cancer survivors to prevent relapse.
The first step down the regulatory pathway for a proprietary metabolite of an approved drug is a Phase 1 study in healthy volunteers, which is what Atossa completed with a 48-patient, dose escalation trial this summer. The trial's purpose is to verify safety, tolerability and to get a better read on the pharmacokinetics of the drug. Being that the patients are healthy, efficacy is of no consideration in this type of study.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/831/atos-stock-gains-on-call-to-discuss-results-from-phase-1-trial.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999.
Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.